Bliss GVS Pharma Limited has announced the incorporation of a wholly owned subsidiary in the Democratic Republic of Congo, marking another step in the company's international expansion strategy. The new subsidiary, THERALIFE PHARMA RDC PRIVATE LIMITED, was established in Kinshasa-Gombe through the company's existing Singapore operations.

Subsidiary Details and Structure

The incorporation was executed through Bliss GVS International PTE Ltd., Singapore, which is itself a wholly owned subsidiary of Bliss GVS Pharma Limited. This step-down subsidiary structure allows the company to expand its operations in the African pharmaceutical market.

Regulatory Compliance and Disclosure

The company has fulfilled its regulatory obligations by informing both the National Stock Exchange of India Ltd. and BSE Limited about this corporate development. The disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key aspects of the regulatory filing include:

• Compliance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
• Adherence to SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023
• Complete disclosure as per Annexure-A requirements

Strategic Implications

The newly incorporated subsidiary operates within the pharmaceutical and health sector, aligning with Bliss GVS Pharma's core business activities. As this is a recent incorporation with a date of December 26, 2025, no turnover data is available for the entity. The establishment of this subsidiary demonstrates the company's commitment to expanding its presence in emerging African markets while maintaining its focus on the pharmaceutical industry.

The incorporation does not involve any acquisition costs or related party transactions, as it represents the creation of a new wholly owned subsidiary rather than the purchase of an existing entity. No governmental or regulatory approvals were required for this incorporation, and the process has been completed as announced.

Bliss GVS Pharma Limited's Board of Directors has approved a significant leadership transition, appointing the company's current Chief Executive Officer, S.N. Kamath, as Managing Director for a three-year term. The decision was made during a board meeting held on December 23, 2025, through video conferencing at the company's registered office.

Board Approval and Appointment Details

The Board of Directors, based on the recommendation of the Nomination and Remuneration Committee, has appointed Mr. S.N. Kamath (DIN: 00140593) as Managing Director for three consecutive years. The appointment is effective from the date of passing the Special Resolution, subject to shareholder approval through postal ballot.

Leadership Profile and Background

Mr. S.N. Kamath brings extensive experience in the pharmaceutical sector to his expanded role. A seasoned professional from Mulki, Karnataka, he began his career in Mumbai before entering the pharmaceutical industry through exports of anti-malarial drugs under GVS Labs. He subsequently acquired Bliss Chemicals Pharmaceuticals, leading to the formation of Bliss GVS Pharma Limited, where he serves as promoter.

Under his leadership, the company has achieved significant milestones:

• Expanded presence to over 60 countries
• Established multiple state-of-the-art manufacturing units
• Received the Pharmexcil Outstanding Export Performance Award (2008-09)
• Maintained close association with company operations and strategic growth

Family Connections and Governance

The appointment involves family relationships within the company's leadership structure. Mr. S.N. Kamath is the father of Dr. Vibha Gagan Sharma and Mrs. Shruti Vishal Rao, both serving as Whole-Time Directors of the company. The disclosure confirms that Mr. Kamath is not debarred from holding the office of Director by virtue of any SEBI order or other regulatory authority.

Meeting Details and Regulatory Compliance

The Board of Directors meeting commenced at 11:47 A.M. and concluded at 13:45 P.M. on December 23, 2025. The board also approved the draft of the Postal Ballot Notice for seeking member approval for Mr. Kamath's appointment as Managing Director. The postal ballot process will enable shareholders to vote on this leadership transition, following regulatory requirements under SEBI guidelines.

The appointment represents a consolidation of leadership roles, combining the Managing Director and Chief Executive Officer positions under Mr. Kamath's stewardship, pending shareholder approval.